EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Evaluating the pharmacokinetics, efficacy and safety of low‐dose cannabidiol

William George Warren iD, Myles Osborn, Andrew Yates, Saoirse Elizabeth O'Sullivan

British Journal of Clinical Pharmacology · 2026-10 · 92 (10) · 3301-3315

DOI: 10.1002/bcp.70691 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift British Journal of Clinical Pharmacology, online erschienen am 19.07.2026. Verfasst von William George Warren und 3 weiteren Autor:innen. Beteiligte Einrichtung: Research and Development, Artelo Biosciences Ltd., Cheshire, UK. Hauptthemen laut MEDLINE: Cannabidiol. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 84 Literaturangaben. Gefördert von: Artelo Biosciences.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Use of non‐prescription cannabidiol (CBD) has increased in recent years, with dose recommendations ranging from ~10 to 70 mg/day. To investigate this trend, many studies have utilized low‐dose CBD paradigms in healthy volunteers and patient populations. Here, we review the pharmacokinetics (PK), pharmacodynamics (PDs), and safety of low‐dose CBD (≤2.5 mg/kg or ≤175 mg/day). PK studies using low‐dose, oral CBD (all included PK studies ≤150 mg) showed that peak ( C max ) and total exposure (area under the curve [AUC]) were 5‐ to 100‐fold lower than a typical 20 mg/kg dose of Epidiolex. PD studies showed very little evidence of physical or neurological effects of low‐dose CBD in healthy volunteers. Drug–drug interactions (DDIs) with Δ9‐tetrahydrocannabinol, amitriptyline, and hydromorphone were observed at low doses (10, 30, 50, 60, 100 mg), which may have implications for patients who are co‐administering non‐prescription CBD with other medications. In randomized controlled trials, there was no evidence that low‐dose CBD ameliorated any of the endpoints measured in patients with Parkinson's, Crohn's, pain, fibromyalgia, stress, ocular hypertension or psoriasis. In sleep disorders (sleep duration, 160 mg), alcohol use disorder (alcohol craving and impaired control, 150 mg/day CBD + 0.41 mg/day THC) and multiple sclerosis (timed walk test and pain, 80 mg/day), CBD improved a small selection of endpoints, but consistent changes were not observed across related endpoints and trials. No studies reported serious adverse events associated with low‐dose CBD, which was well tolerated. In conclusion, low doses of CBD show very little evidence of any biological effect or therapeutic value.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CannabidiolHumansDrug InteractionsDose-Response Relationship, DrugAdministration, OralArea Under CurveRandomized Controlled Trials as Topic

Stichwörter der Autor:innen

cannabidiolclinicalefficacylow‐dosepharmacokinetics

Substanzen

Cannabidiol

Autor:innen und Institutionen

  • Research and Development, Artelo Biosciences Ltd., Cheshire, UK.

ORCID-Profile: William George Warren

Förderung

  • Artelo Biosciences

Zitieren

APA

Warren, W. G., Osborn, M., Yates, A., & O'Sullivan, S. E. (2026). Evaluating the pharmacokinetics, efficacy and safety of low‐dose cannabidiol. British Journal of Clinical Pharmacology, 92(10), 3301-3315. https://doi.org/10.1002/bcp.70691

Vancouver

Warren WG, Osborn M, Yates A, O'Sullivan SE. Evaluating the pharmacokinetics, efficacy and safety of low‐dose cannabidiol. British Journal of Clinical Pharmacology. 2026;92(10):3301-3315. doi:10.1002/bcp.70691

BibTeX
@article{Warren2026,
  author = {Warren, William George and Osborn, Myles and Yates, Andrew and O'Sullivan, Saoirse Elizabeth},
  title = {Evaluating the pharmacokinetics, efficacy and safety of low‐dose cannabidiol},
  journal = {British Journal of Clinical Pharmacology},
  year = {2026},
  volume = {92},
  number = {10},
  pages = {3301--3315},
  doi = {10.1002/bcp.70691}
}
Kostenlos starten →